[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"super-refractory-status-epilepticus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:super-refractory-status-epilepticus":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100631136","kd-treatment-for-super-refractory-status-epilepticus-100631136",false,"NCT07496749","KD Treatment for Super-refractory Status Epilepticus","Ketogenic Diet Treatment for Super-refractory Status Epilepticus: a Multicenter, Prospective, Randomized, Controlled Trial","KD","Inclusion Criteria:\n\n* Patients diagnosed with super-refractory status epilepticus (SRSE), in whom status epilepticus (SE) persists or recurs after the initial treatment for SE-including intravenous benzodiazepines, an anti-seizure medication (ASM, such as valproate, levetiracetam, or phenobarbital), and an anesthetic (e.g., propofol) administered continuously for 24 hours-fails to terminate the episode, or when SE recurs upon reduction of the anesthetic.\n* Age between 14 and 80 years, regardless of gender.\n* The patient's legal guardian has provided signed informed consent.\n\nExclusion Criteria:\n\n* Patients with lipid metabolism disorders, including defects in fatty acid transport and beta-oxidation, such as carnitine deficiency (primary) and carnitine-related enzyme deficiencies (including carnitine palmitoyltransferase \\[CPT\\] I and II deficiency, carnitine translocase deficiency), fatty acid oxidation disorders (including beta-oxidation defects), short-chain acyl-CoA dehydrogenase deficiency (SCAD), medium-chain acyl-CoA dehydrogenase deficiency (MCAD), long-chain acyl-CoA dehydrogenase deficiency (LCAD), long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, medium-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, pyruvate carboxylase deficiency, and porphyria.\n* Intolerance to enteral feeding (e.g., intestinal obstruction).\n* Receipt of propofol infusion within 24 hours.\n* Hemodynamic instability (systolic blood pressure \\\u003C90 mmHg or diastolic blood pressure \\\u003C60 mmHg, requiring high-dose vasopressors for maintenance).\n* Liver failure (aspartate aminotransferase \\[AST\\], alanine aminotransferase \\[ALT\\], blood ammonia \\>5 times the upper limit of normal; total bilirubin \\>10 mg\u002FdL \\[171 μmol\u002FL\\]).\n* Pancreatitis.\n* Pregnancy.\n* Metabolic instability (blood glucose \\\u003C3.1 mmol\u002FL, arterial blood pH \\\u003C7.2, serum sodium \\\u003C120 or \\>160 mmol\u002FL).\n* Septic shock.\n* Complicated by diabetes insipidus.\n* Status epilepticus caused by hypoxic-ischemic brain injury.","ALL","14 Years","80 Years",{"count":21,"type":22},84,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of the study is to investigate to evaluate the efficacy and safety of ketogenic diet (KD) as an adjunctive therapy in patients with Super Refractory Status Epilepticus (SRSE) in the intensive care unit (ICU).",[28],"Super-refractory Status Epilepticus",[30,31,32,33,34],"ketogenic diet","status epilepticus","refractory status epilepticus","encephalitis","intensive care unit","RECRUITING","2026-05-12",{"date":38,"type":39},"2026-05-15","ACTUAL",{"date":41,"type":39},"2025-10-20",{"date":43,"type":22},"2027-03-01",{"name":45,"class":46},"Xuanwu Hospital, Beijing","OTHER",14]